BrainStorm Appoints Prof. Ole Isacson to Scientific Advisory Board; Award Winning Neurologist and Advisor to Michael J. Fox Foundation to Provide Compelling Research Direction

Business Wire, March 24, 2005

TEL AVIV, Israel -- BrainStorm Cell Therapeutics (OTCBB:BCLI), an emerging company in stem cell therapeutics for neurological diseases, today announced that Prof. Ole Isacson, internationally renowned neurologist and pioneering innovator in cell therapeutic strategies for neural regeneration, was appointed to the Company's Scientific Advisory Board.

Dr. Isacson is a Professor of Neurology (Neuroscience) at Harvard Medical School, Director of the Center for Neuroregeneration Research and the McLean Hospital/Harvard University Udall Parkinson's Disease Research Center of Excellence, and a Chair of the Regeneration and Repair Program, Harvard Center for Neurodegeneration and Repair. Professor Isacson, together with his team at the Harvard Medical School affiliated laboratory, works on scientific models and new concepts for therapies for neurodegenerative diseases including cell replacement, regeneration and protection, which have resulted in discoveries that led to clinical trials for Parkinson's and Huntington's diseases.

He is a Receiving Editor of the European Journal of Neuroscience, past President of the American Society for Neural Transplantation and Repair, member elect of the American Academy of Neurology, the American Society of Transplantation and the council of the International Cell Transplantation Society. He serves as a reviewer and advisor to the NIH, DOD, Parkinson community groups and the Michael J. Fox Foundation. He has received international prizes, research awards and lectureships, including the Royal Swedish Academy of Sciences Lindahl Award and the Bernard Sanberg Memorial Award. He is author and co-author of over 200 scientific research publications and 3 books in neuroscience and neurology. Dr. Isacson holds an M.D. and a Dr. of Medical Science degree in Medical Neurobiology form the University of Lund (Sweden), and did his Post Doctoral training in Neurobiology at the University of Cambridge (England).

"Cell therapy holds the potential to revolutionize the treatment of Parkinson's disease and other neurodegenerative disorders. I look forward to working with Prof. Melamed and BrainStorm's scientific team and advise them in their efforts to develop their NurOwn(TM) technology through studies in animal models and, hopefully, in humans to effectuate their goal of utilizing autologous bone marrow stem cells to create functional regenerating neurons," stated Prof. Isacson.

"We are excited and honored that Prof. Isacson is joining our Scientific Advisory Board. His ground-breaking research work in the development of cell therapeutic approaches to Parkinson's disease along with his clinical expertise are perfectly matched to support BrainStorm's mission and development activities. We believe that his guidance will be of significant value as we forge ahead with our development program through animal studies towards clinical implementation ," stated, Yaffa Beck, CEO.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team of prominent neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The company's initial focus is on developing treatments for Parkinson's Disease.

About Stem Cell Therapy

Stem cells are non-specialized cells with a remarkable potential for both self-renewal and differentiation into cell types with a specialized function, such as muscle, blood or brain cells. Stem cells may be sourced from fetal or embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of embryonic stem cells, has become the center of significant ethical and moral debate. In contrast, use of adult stem cells does not face the same moral or legal controversy. Stem cell therapy aims to "cure" disease by replacing the 'diseased' cells with 'healthy' cells derived from stem cells. This approach has the potential to revolutionize medicine and, if successful, the implied commercial opportunities are great. Currently, both embryonic stem cells (ESC) and adult stem cells (ASC) are being explored as the potential basis for multiple cell therapy products.

About Parkinson's Disease

Parkinson's Disease (PD), which was first described by James Parkinson in 1817 as "the shaking palsy", is a chronic, progressive neurodegenerative disorder, affecting the brain cells responsible for production of dopamine. The symptoms include tremors, rigidity, slowness of movement and impaired balance. Over four million people in the developed world, including as many as 1.5 million Americans, mainly over the age of 65, are diagnosed with PD. That figure is predicted to rise by 10% by 2010. Pharmaceutical treatments of PD with an estimated combined annual market value of $4 billion, are insufficient to meet patient needs. The search for more effective treatments continues.